Skip to main content
. Author manuscript; available in PMC: 2020 Jan 15.
Published in final edited form as: Clin Cancer Res. 2018 Sep 10;25(2):663–673. doi: 10.1158/1078-0432.CCR-18-0926

Figure 1: Generation and testing of MET resistant GBM cells and GSCs.

Figure 1:

A). U87, B). U373 and C). GSC827 cells were exposed to increasing concentrations of either crizotinib or Onartuzumab (Onart) until resistance was confirmed at 100 nM for crizotinib-resistant (CR) and 300 nM for Onart-resistant (OR) respectively by trypan blue assay. The data confirm the generation of MET inhibitor resistant cells. D). U87 WT & CR cells were treated with crizotinib (100 nM) for 48 hr. Cell proliferation was assessed by cell counting over a period of 5 days and growth curves were established*, P < 0.05.